Viracta Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Viracta Therapeutics announced participation in the 20th Annual Needham Virtual Healthcare Conference from April 12-15, 2021. The Company will present on April 14, 2021, at 3:45 PM ET, focusing on its precision oncology efforts targeting virus-associated malignancies. Viracta's investigational drug, nanatinostat, is in a Phase 2 trial for EBV-positive lymphoma, combined with valganciclovir, and is exploring applications for other EBV-related cancers. For more details, visit www.viracta.com.

News Market Reaction – VIRX

-1.58%

-1.58% Session move

In the trading session that priced this news, VIRX declined 1.58%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, April 8, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that Company management will present at the 20^th Annual Needham Virtual Healthcare Conference taking place April 12-15, 2021. The Company will also participate in one-on-one investor meetings at the conference.

Details on the presentation can be found below.

Date:	Wednesday, April 14, 2021
Time:	3:45 PM ET
Format:	Corporate presentation

About Viracta Therapeutics, Inc.
Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphoma. Viracta is pursuing application of this inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.

For additional information please visit www.viracta.com.

Investor Relations Contact:	Company Contact:
Joyce Allaire	Dan Chevallard
LifeSci Advisors	Chief Operating Officer and Chief Financial Officer
jallaire@lifesciadvisors.com	dchevallard@viracta.com
(212) 915-2569	(858) 771-4193

 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/viracta-therapeutics-to-present-at-the-20th-annual-needham-virtual-healthcare-conference-301264794.html

SOURCE Viracta

FAQ

What is Viracta's presentation date at the Needham Virtual Healthcare Conference?

Viracta will present on April 14, 2021.

What time will Viracta present at the conference?

The presentation will be at 3:45 PM ET.

What is Viracta's focus in oncology?

Viracta focuses on virus-associated malignancies.

What drug is Viracta currently evaluating in clinical trials?

Viracta is evaluating nanatinostat in a Phase 2 trial for EBV-positive lymphoma.

What other cancers is Viracta targeting with its therapies?

Viracta is targeting nasopharyngeal carcinoma, gastric carcinoma, and other EBV-associated malignancies.